Here's what's coming up this week on Contemporary OB/GYN®
The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.
The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.
The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.
Check baack soon for additional updates.